MedTrace Logo

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

NCT03263130 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-10-27

No results posted yet for this study

Summary

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).

Conditions

  • COPD, Emphysema, Asthma COPD Overlap
  • Emphysema

Interventions

OTHER

As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap

Sponsors & Collaborators

  • Gelb, Arthur F., M.D.

    lead INDIV

Principal Investigators

  • Arthur F Gelb, MD · Clin Prof Geffen School of Medicine at UCLA Medical Center

  • Arthur F Gelb, MD · Clin Prof Geffen School of Medicine at UCLA Medical Center

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2027-01-01
Completion
2027-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03263130 on ClinicalTrials.gov